TG Therapeutics Missed Expectations

TG Therapeutics (TGTX) reported earnings of $0.03 per share on revenue of $120.86 million for the first quarter ended March 2025. The consensus earnings estimate was $0.18 per share on revenue of $118.50 million. The Earnings Whisper number was $0.21 per share. The company missed expectations by 85.71% while revenue grew 90.40% on a year-over-year basis.

The company said it expects 2025 revenue of approximately $575.0 million. The company's previous guidance was revenue of approximately $540.0 million and the current consensus revenue estimate is $545.6 million for the year ending December 31, 2025.

TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.